Edition:
United Kingdom

ArQule Inc (ARQL.OQ)

ARQL.OQ on NASDAQ Stock Exchange Global Market

10.78USD
3:48pm BST
Change (% chg)

$0.21 (+1.99%)
Prev Close
$10.57
Open
$10.60
Day's High
$10.80
Day's Low
$10.52
Volume
91,113
Avg. Vol
720,656
52-wk High
$12.21
52-wk Low
$2.23

Latest Key Developments (Source: Significant Developments)

ArQule Announces Pricing Of $90 Million Public Offering Of Common Stock
Tuesday, 25 Jun 2019 

June 25 (Reuters) - ArQule Inc ::ARQULE ANNOUNCES PRICING OF $90 MILLION PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 9.25 MILLION COMMON SHARES PRICED AT $9.75PER SHARE.  Full Article

ArQule Reports Q4 Loss Per Share $0.09
Monday, 5 Mar 2018 

March 5 (Reuters) - ArQule Inc ::ARQULE REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.09.SEES FY 2018 REVENUE $3.0 MILLION TO $4.0 MILLION.SEES FY 2018 LOSS PER SHARE $0.30 TO $0.34.REVENUES FOR QUARTER ENDED DECEMBER 31, 2017, WERE ZERO, COMPARED WITH REVENUES OF $1.2 MILLION FOR THE QUARTER ENDED DECEMBER 31, 2016.  Full Article

Roivant Sciences And Arqule Enter Into License Agreement For Derazantinib In China
Wednesday, 7 Feb 2018 

Feb 7 (Reuters) - Arqule Inc ::ROIVANT SCIENCES AND ARQULE ENTER INTO LICENSE AGREEMENT FOR DERAZANTINIB IN CHINA.ARQULE INC - ‍DEAL TERMS INCLUDE AN UPFRONT PAYMENT TO ARQULE OF $3 MILLION AND AN ADDITIONAL $2.5 MILLION DEVELOPMENT MILESTONE WITHIN FIRST YEAR​.ARQULE INC - ARQULE IS ALSO ELIGIBLE FOR REGULATORY AND COMMERCIAL MILESTONES AND ROYALTIES ON FUTURE SALES OF DERAZANTINIB IN GREATER CHINA.ARQULE INC - COLLABORATION BETWEEN CO AND ROIVANT WILL EXPAND CLINICAL DEVELOPMENT OF DERAZANTINIB.ARQULE - ‍ GRANTED A ROIVANT UNIT AN EXCLUSIVE LICENSE TO DEVELOP, COMMERCIALIZE DERAZANTINIB IN PEOPLE'S REPUBLIC OF CHINA, HONG KONG, MACAU, TAIWAN​.  Full Article

ArQule Files For Offering Of Up To 17.1 Million Shares
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Arqule Inc ::ARQULE INC FILES FOR OFFERING OF UP TO 17.1 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING.  Full Article

Arqule reports Q3 loss per share $0.09
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Arqule Inc :Arqule reports third quarter 2017 financial results.Q3 loss per share $0.09.Sees FY 2017 loss per share $0.38 to $0.40.Q3 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S.Arqule Inc - ‍Expects to end 2017 with between $47 and $49 million in cash and marketable securities​.Arqule Inc - ‍For 2017, Arqule expects net use of cash to range between $25 and $27 million​.  Full Article

ArQule announces $9.5 mln private placement of preferred stock
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - ArQule Inc :ArQule announces $9.5 million private placement of preferred stock.ArQule Inc - to use proceeds to advance clinical trials related to proprietary pipeline, including derazantinib, miransertib, ARQ 531 & ARQ 751​.  Full Article

Arqule announces $15.7 mln private placement of common stock
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Arqule Inc :Arqule announces $15.7 million private placement of common stock.Arqule Inc - ‍intends to use net proceeds from offering to advance clinical trials related to its proprietary pipeline​.Arqule Inc - expects in first part of 2019 to obtain arq 531 PK/PD data from phase 1a trial in patients with refractory b-cell malignancies.Arqule inc - ‍company currently anticipates cash and marketable securities to provide funding into 2019​.Arqule Inc - ‍expects to end 2017 with between $38 and $40 million in cash and marketable securities​.Arqule Inc - expects in first part of 2019 to initiate phase 1b proof of concept trial​ for arq 531.Arqule-Expects in first part of 2019 to present authorities with proof of concept data to initiate registrational trial in proteus syndrome​ for ARQ 092.  Full Article

Arqule Q2 loss per share $0.10
Friday, 4 Aug 2017 

Aug 4 (Reuters) - Arqule Inc :Arqule reports second quarter 2017 financial results.Q2 loss per share $0.10.Q2 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S.Arqule Inc - ‍at june 30, 2017, company had a total of approximately $31 million in cash, equivalents and marketable securities​.Arqule Inc - ‍revenues for quarter ended june 30, 2017, were zero compared with revenues of $1.1 million for quarter ended June 30, 2016​.  Full Article

BRIEF-Basilea Announces Collaboration To Study Derazantinib And Atezolizumab In Urothelial Cancer

* BASILEA ANNOUNCES COLLABORATION TO STUDY DERAZANTINIB AND ATEZOLIZUMAB (TECENTRIQ®) IN UROTHELIAL CANCER